Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.
暂无分享,去创建一个
W Steinbrich | I Mader | W. Steinbrich | L. Kappos | E. Radue | I. Mader | J. Seelig | E W Radue | L Kappos | J Seelig | G Hagberg | W Roser | W. Roser | G. Hagberg
[1] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[2] P. Dupont,et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis , 1997, Multiple sclerosis.
[3] J. denBoer,et al. A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging , 1995, Multiple sclerosis.
[4] P. Hecke,et al. Human brain proton localized NMR spectroscopy in multiple sclerosis , 1991, Magnetic resonance in medicine.
[5] H. Larsson,et al. The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.
[6] William H. Oldendorf,et al. N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.
[7] D. L. Collins,et al. Statistics for Investigation of Multimodal MR Imaging Data and an Application to Multiple Sclerosis Patients , 1996, NMR in biomedicine.
[8] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[9] W. Roser. Reproducibility of metabolite peak areas in 1H MRS of the human brain. , 1997, Magnetic resonance imaging.
[10] P. Matthews,et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.
[11] R E Lenkinski,et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis , 1994, Magnetic resonance in medicine.
[12] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[13] Jullie W Pan,et al. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.
[14] S. Provencher. Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.
[15] R. Lenkinski,et al. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. , 1996, AJNR. American journal of neuroradiology.
[16] M. Castillo,et al. Extraneous lipid contamination in single-volume proton MR spectroscopy: phantom and human studies. , 1997, AJNR. American journal of neuroradiology.
[17] J S Wolinsky,et al. Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.
[18] J. Frahm,et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.
[19] R E Lenkinski,et al. MR proton spectroscopy in multiple sclerosis. , 1992, AJNR. American journal of neuroradiology.
[20] B J Soher,et al. Quantitation of automated single‐voxel proton MRS using cerebral water as an internal reference , 1996, Magnetic resonance in medicine.
[21] L. Kappos,et al. Proton MRS of Gadolinium‐enhancing MS Plaques and Metabolic Changes in Normal‐Appearing White Matter , 1995, Magnetic resonance in medicine.
[22] E. Cho,et al. Multiple sclerosis: remyelination of nascent lesions. , 1993, Annals of neurology.
[23] Joseph Granot,et al. Selected Volume Excitation Using Stimulated Echoes (VEST). Applications to spatially localized spectroscopy and imaging , 1986 .
[24] E. Cabanis,et al. In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis. , 1996, Journal of neuroradiology. Journal de neuroradiologie.
[25] N. Herschkowitz,et al. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. , 1991, Developmental neuroscience.
[26] H. Bruhn,et al. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.
[27] R. Kimmich,et al. Volume-selective multipulse spin-echo spectroscopy , 1987 .
[28] P M Matthews,et al. Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient , 1997, Neurology.
[29] G. Barker,et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.
[30] J. Frahm,et al. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites , 1989, Magnetic resonance in medicine.
[31] Anne-Marie Landtblom,et al. Proton MR Spectroscopy and MR Imaging in Acute and Chronic Multiple Sclerosis — Ringlike Appearances in Acute Plaques , 1996, Acta radiologica.
[32] O Henriksen,et al. Absolute quantitative proton NMR spectroscopy based on the amplitude of the local water suppression pulse. Quantification of brain water and metabolites , 1994, NMR in biomedicine.
[33] G. Fein,et al. Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.
[34] Chrit T. W. Moonen,et al. Highly Effective Water Suppression for in vivo proton NMR Spectroscopy (DRYSTEAM) , 1990 .
[35] A. Thompson,et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.
[36] R. Tarducci,et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: results of a preliminary study , 1998, Journal of neurology, neurosurgery, and psychiatry.
[37] O Henriksen,et al. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. , 1993, Magnetic resonance imaging.
[38] D. Paty,et al. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products , 1993, The Lancet.
[39] J. Hennig,et al. Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy , 1992, NMR in biomedicine.
[40] M W Weiner,et al. 1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.
[41] P M Matthews,et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.
[42] P. Matthews,et al. Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.
[43] Jia Newcombe,et al. High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions , 1995, Journal of neurochemistry.
[44] D Origgi,et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. , 1998, AJNR. American journal of neuroradiology.
[45] P M Matthews,et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.
[46] I. Marshall,et al. Reproducibility of metabolite peak areas in 1H MRS of brain. , 1996, Magnetic resonance imaging.
[47] R E Lenkinski,et al. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease. , 1996, AJNR. American journal of neuroradiology.
[48] Lublin Fd,et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .
[49] E Moore,et al. Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. , 1998, Magnetic resonance imaging.
[50] G. Barker,et al. Detection of myelin breakdown products by proton magnetic resonance spectroscopy , 1993, The Lancet.
[51] J. Olesen,et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis , 1991, Magnetic resonance in medicine.
[52] U. Klose. In vivo proton spectroscopy in presence of eddy currents , 1990, Magnetic resonance in medicine.
[53] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[54] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[55] J. Frahm,et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.
[56] W. Steinbrich,et al. [Results and consequences of frequent quality control of quantitative clinical 1H-MR-spectroscopy]. , 1997, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.